To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
XenTech wishes you a happy new year!
Because the goodwill of those we serve is the foundation of our success. It is a real pleasure at this holiday time to say « Thank you! ». We wish you lot of happiness and prosperity in 2017.
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....